Company news
Roivant Sciences Ltd. (NASDAQ:ROIV) news
Every Roivant Sciences Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026
Roivant Sciences : Annual Report for Fiscal Year Ending March 31, 2025 (Form 10-K)
May 20, 2026
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday,...
May 11, 2026
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
April 2, 2026
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study ...
April 2, 2026
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
March 3, 2026
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
March 3, 2026
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associate...
February 6, 2026
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Qua...
February 6, 2026
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
February 6, 2026
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, ...
January 23, 2026
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
January 23, 2026
Immunovant Announces Pricing of $550 Million Common Stock Financing
December 11, 2025
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
December 11, 2025
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
November 10, 2025
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 1...
October 27, 2025
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, ...
October 27, 2025
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositi...
September 17, 2025
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
September 11, 2025
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstit...
September 4, 2025
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Grave...
September 3, 2025
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
August 11, 2025
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
July 28, 2025
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
June 16, 2025
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in De...
June 9, 2025
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
May 29, 2025
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, ...
May 15, 2025
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Dise...
April 21, 2025
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Stu...
March 19, 2025
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chroni...
March 18, 2025
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board
February 25, 2025
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
February 10, 2025
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
January 29, 2025
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
December 3, 2024
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
December 3, 2024
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
November 12, 2024
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, ...
October 29, 2024
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
October 28, 2024
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cy...
September 10, 2024
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Resp...
September 10, 2024
Roivant Provides Update on Graves’ Disease Development Program
September 9, 2024
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
August 8, 2024
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
July 25, 2024
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
May 30, 2024
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday,...
May 16, 2024
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Rep...
April 2, 2024